Eagle Bay Advisors LLC Supernus Pharmaceuticals, Inc. Transaction History
Eagle Bay Advisors LLC
- $163 Million
- Q2 2024
A detailed history of Eagle Bay Advisors LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Eagle Bay Advisors LLC holds 229 shares of SUPN stock, worth $7,873. This represents 0.0% of its overall portfolio holdings.
Number of Shares
229
Previous 285
19.65%
Holding current value
$7,873
Previous $9,000
33.33%
% of portfolio
0.0%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding SUPN
# of Institutions
255Shares Held
59.2MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$357 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$211 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$181 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.87MShares$98.6 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$92.1 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.84B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...